Article Versions Notes

Mauro FR, Scalzulli PR, Scarfò L, Minoia C, Murru R, Sportoletti P, Frigeri F, Albano F, Di Renzo N, Sanna A, et al. Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study. Cancers. 2024; 16(6):1228. https://doi.org/10.3390/cancers16061228

Mauro, Francesca Romana, Potito Rosario Scalzulli, Lydia Scarfò, Carla Minoia, Roberta Murru, Paolo Sportoletti, Ferdinando Frigeri, Francesco Albano, Nicola Di Renzo, Alessandro Sanna, and et al. 2024. "Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study" Cancers 16, no. 6: 1228. https://doi.org/10.3390/cancers16061228

Mauro, F. R., Scalzulli, P. R., Scarfò, L., Minoia, C., Murru, R., Sportoletti, P., Frigeri, F., Albano, F., Di Renzo, N., Sanna, A., Laurenti, L., Massaia, M., Cassin, R., Coscia, M., Patti, C., Pennese, E., Tafuri, A., Chiarenza, A., Galieni, P., ... Molica, S. (2024). Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study. Cancers, 16(6), 1228. https://doi.org/10.3390/cancers16061228